TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it will exhibit and feature the Senhance™ Surgical Robot System (the "Senhance") at the 45th American Association of Gynecologic Laparoscopists (AAGL) Global Congress. The congress will be held on November 16-18, 2016 in Orlando, FL. The Senhance will be available for surgeon evaluations at the congress. Surgeons may schedule system evaluations by signing up at the TransEnterix booth. Dr. Salvatore Gueli Alletti from the Division of Gynecologic Oncology at the Catholic University of the Sacred Heart in Rome, Italy, will headline a special symposium dedicated to the clinical experience of the Senhance in Gynecologic Surgery. The symposium will be held on the morning of Wednesday, November 16, 2016, and participants must register through the AAGL to attend. The Senhance carries the CE Mark for use in general surgery, gynecology, urology and thoracic surgery but is not available for sale in the US. TransEnterix is preparing a 510(k) submission for the Senhance. About TransEnterix TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States. For more information, visit the TransEnterix website at www.transenterix.com. Forward Looking Statements This press release includes statements relating to The Senhance™ Surgical Robotic System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether and when we will prepare a 510(k) submission for the Senhance Surgical Robotic System. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 3, 2016 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.